Eli Lilly (LLY)
(Delayed Data from NYSE)
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $780.49 +4.11 (0.53%) 8:36 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $780.49 +4.11 (0.53%) 8:36 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Wall Street Set to Post Fifth Winning Month Amid Volatility
by Zacks Equity Research
Wall Street is likely to record the fifth consecutive winning month despite volatility.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.
Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics
by Zacks Equity Research
Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $772.78, moving +1.33% from the previous trading session.
Time to be "Overweight" Viking Therapeutics
by Andrew Rocco
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
by Kinjel Shah
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Amazon (AMZN) Boosts Pharmacy Efforts With Lilly's Partnership
by Zacks Equity Research
Amazon (AMZN) teams up with Lilly to deliver drug prescriptions that are sent to the latter's direct-to-consumer service, LillyDirect.
Lilly (LLY) Partners Amazon to Deliver Drugs Like Zepbound
by Zacks Equity Research
Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.
Eli Lilly (LLY) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Eli Lilly (LLY) reachead $757.84 at the closing of the latest trading day, reflecting a +0.38% change compared to its last close.
The Zacks Analyst Blog Highlights Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly
by Zacks Equity Research
Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly are part of the Zacks top Analyst Blog.
Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
by Zacks Equity Research
Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.
Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab
by Zacks Equity Research
The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
S&P 500 Soars to New Highs: 5 Best Stocks YTD
by Sweta Killa
The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
by Zacks Equity Research
Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Viking (VKTX) Stock Down on Novo Nordisk's Obesity Pill Data
by Zacks Equity Research
Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Zacks Market Edge Highlights: NVDA, DELL, LLY, CMG and CAVA
by Zacks Equity Research
NVDA, DELL, LLY, CMG and CAVA have been highlighted in this Market Edge article.
Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Buy Red-Hot Stocks Now or Wait?
by Tracey Ryniec
After a mesmerizing rally to start 2024, is it too late to buy the hottest stocks?